NCT06015802Recruiting
Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors
Source: ClinicalTrials.gov · Last updated 29 Aug 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
As the clinical manifestations of pituitary neuroendocrine tumors vary greatly, 2.7-15% of them are resistant to conventional treatments such as surgery, drug therapy and radiotherapy, and often relapse or regrow in the early postoperative period, which is invasive and has a poor prognosis. Therefore, it is important to find imaging, histological or serum molecular markers for early prediction of the invasiveness and clinical prognosis of pituitary neuroendocrine tumors. The aim of this study is to observe the changes of biomarkers and imaging features in serum or tissues of pituitary neuroendocrine tumors during the course of disease and treatment, and to explore the biomarkers and imaging features that can predict the proliferation, progression and recurrence risk of pituitary neuroendocrine tumors after medical or surgical treatment.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 24 Aug 2023
- Start date
- 1 Apr 2021
- Primary completion date
- 31 Mar 2024
- Lead sponsor
- Sun Yat-sen University
- Diseases
- Neuroendocrine tumours
- NCT number
- NCT06015802
What you commit to
- Study type: Observational
- Planned participants: 300
- From 1 Apr 2021 to the primary completion date, 31 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous pathological specimen suggested pituitary carcinoma.
- always have received radiation and chemotherapy or immune and targeted therapy of the patients.
- within one month before the screening for major surgery, or within 3 months before screening for patients with sphenoid pituitary surgery.
Other illness
- with known genetic syndrome can cause excessive secretion of hormones (such as Carney syndrome, McCune - Albright syndrome, multiple endocrine neoplasia type 1, acute interstitial pneumonia) patients.
- peripheral glands or other solid tumors in patients with severe disease or blood system.
- serious organ damage such as heart, kidney, liver, etc.
- with severe mental or nervous system disease.
Lab values
- serious high blood glucose or poorly controlled hypertension or emergency patients.
Other
- there are ectopic neuroendocrine tumor patients.
- crisis of gland function (the pituitary gland, thyroid crisis, adrenal crisis).
Who the study is looking for
- Patients with pituitary neuroendocrine tumors: pituitary adenoma was diagnosed by clinical imaging, with or without pituitary hormone secretion function was confirmed by pituitary hormone detection.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| endocrinology department of the first affiliated hospital of Sun Yat-sen University Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.